‘A great day for science and humanity’; Pfizer’s COVID-19 vaccine is found to be 90% effective

Pfizer and BioNTech have today announced their new vaccine candidate (BNT162b2) is 90% effective against SARS-CoV-2. This mRNA-based vaccine has shown to be effective in participants without prior knowledge of SARS-CoV-2.
Pfizer has also recently dropped the 32-case analysis and aimed to carry out the first interim analysis with a minimum of 62 cases. After this discussion, the DMC conducted its first analysis of these cases. The DMC discovered a vaccine efficacy rate above 90% just 7 days after the second dose, meaning that protection is achieved 28 days after the initial vaccination. As the study is only in its clinical trial, the final vaccine efficacy percentage could vary.

So far, however, the DMC has yet to report any serious safety concerns and has allowed the study to continue to collect extra safety and efficacy data. After this, the data will be discussed with other regulatory authorities worldwide.

I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor. We could not have come this far without the tremendous commitment of everyone involved.”

Related Stories
Nasal spray COVID-19 vaccine shows promising results in mice
New method could help increase effectiveness of vaccines against coronavirus
Sinopharm's candidate SARS-CoV-2 vaccine BBIBP-CorV shows promise in clinical trials
“The first interim analysis of our global Phase 3
for more:https://bit.ly/36COtPu